Startup Dossier
Step Pharma
French biotech developing next-generation targeted therapies that selectively destroy cancer cells while sparing healthy ones. Its lead programs focus on inhibiting CTPS1, a key enzyme required for DNA synthesis in cancer cells, with promising results across hematologic cancers, solid tumors, and autoimmune diseases.
About
French biotech developing next-generation targeted therapies that selectively destroy cancer cells while sparing healthy ones. Its lead programs focus on inhibiting CTPS1, a key enzyme required for DNA synthesis in cancer cells, with promising results across hematologic cancers, solid tumors, and autoimmune diseases.
Structural DNA
Legal Name
Step Pharma
SIREN
802795906
Founders & Team
Funding Lineage
Series C
6 investors
€38.0M
Oct 2025
Series B
Bpifrance (Lead)
€35.0M
Mar 2021
Programs
i-Lab
French Tech Next 40/120